Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of Vienna
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has received a kidney transplantation
\> 18 years of age
No SARS-CoV-2 spike protein antibodies four weeks after at least three previous vaccine doses
Maintenance immunosuppression with mycophenolate or azathioprine
You may not be if
acute illness with fever
Prior documented infection with SARS-CoV-2
triple anticoagulation therapy
Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)
Subject has known sensitivity or intolerance to any of the products to be administered for the purpose of this study
Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with the study procedures
Subject is pregnant or breast feeding
SARS-CoV-2 spike protein antibodies four weeks after the 3rd last vaccination \> 0.8 BAU/mL
Clareo Health | Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients
